
Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative.
Investor Presentation Deck
Tetra Investor Presentation
Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative.
Investor Presentation Deck
Tetra Investor Presentation
VANCOUVER, Washington, Aug. 08, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the […]
Company in position for pre-sales license inspection, last step to issuance of a Sales License FSD Pharma Inc. (“FSD Pharma” or the “Company”) (OTC: FSDDF) (cse:HUGE)(fra:0K9) is pleased to announce that its wholly-owned subsidiary, FV […]
FinCanna Capital (OTC: FNNZF) CEO Andriyko Herchak discusses the cannabis royalty model, and company’s focus on the marijuana market Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.